Table 1.
Summary of all the selected studies.
| No. | Author | Year | Therapy | N | AChR-ab + | Musk-ab + | Seronegative | Outcomes |
|---|---|---|---|---|---|---|---|---|
| 1 | H. Wu | 2020 | Tacrolimus | 24 | 18 | 0 | 6 | QMG, MG-ADL |
| 2 | M. Oyama | 2020 | Eculizumab | 11 | 11 | 0 | 0 | QMG, MGFA-PIS, MG-ADL |
| 3 | T. Levine | 2019 | Eculizumab | 13 | 13 | 0 | 0 | MGC |
| 4 | J. Howard* | 2017 | Eculizumab | 62 | 62 | 0 | 0 | QMG, MG-ADL |
| 5 | R. Mantegazza* | 2021 | Eculizumab | 117 | 117 | 0 | 0 | MGFA-PIS |
| 6 | J. Howard | 2013 | Eculizumab | 14 | 14 | 0 | 0 | QMG, MG-ADL |
| 7 | R. Govindarajan | 2020 | Eculizumab | 15 | 15 | 0 | 0 | MG-ADL |
| 8 | D. Anderson | 2016 | Rituximab | 14 | 5 | 6 | 3 | MMT |
| 9 | k. Choi | 2019 | Rituximab | 17 | 9 | 6 | 2 | MGFA-PIS |
| 10 | S. Jing | 2019 | Rituximab | 15 | 13 | 1 | 1 | QMG, MGFA-PIS, MG-ADL |
| 11 | R. Topakian | 2019 | Rituximab | 56 | 39 | 14 | 3 | MGFA-PIS |
| 12 | O. Landon-Cardinal | 2018 | Rituximab | 11 | 11 | 0 | 0 | QMG |
| 13 | K. Robeson | 2017 | Rituximab | 16 | 16 | 0 | 0 | MGFA-PIS |
| 14 | T. Litchman | 2020 | Rituximab | 33 | 17 | 16 | 0 | MGFA-PIS |
| 15 | S. Brauner | 2020 | Rituximab | 34 | 28 | 0 | 6 | QMG |
| 16 | K. Rejdak | 2020 | Cladribine | 13 | 13 | 0 | 0 | MGC |
*
Study 5 was the open-label extension of Study 4. AChR, acetylcholinergic receptor; Musk, muscle-specific tyrosine kinase; MG-ADL, Myasthenia Gravis-Activities of Daily Living; MGC, Myasthenia Gravis Composite; MGFA-PIS, Myasthenia Gravis Foundation of America post-intervention status; MMT, manual muscle test; QMG, Quantitative myasthenia gravis.